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Abstract
Direct sequencing and reverse hybridization are currently the main methods for detecting drug-resistance mutations of hepatitis B virus
(HBV). However, these methods do not enable haplotype analysis so they cannot be used to determine whether the mutations are co-
located on the same viral genome. This limits the accurate identiﬁcation of viral mutants that are resistant to drugs with a high genetic
barrier. In our current study, ultra-deep pyrosequencing (UDPS) was used to detect HBV drug-resistance mutations in 25 entecavir-
treated and ﬁve treatment-naive patients. Of the 25 entecavir-treated patients, 18 had experienced virological breakthrough and two
exhibited reduced susceptibility to entecavir. The results obtained by UDPS were compared with those of direct sequencing, and the
haplotypes of the drug-resistant HBV mutants were analysed. The average number of reads per patient covering the region in which
drug-resistance mutations are located was 1735 (range 451–4526). UDPS detected additional drug-resistance mutations not detected by
direct sequencing in 19 patients (mutation frequency range 1.1–23.8%). Entecavir-resistance mutations were found to be co-located on
the same viral genome in all 20 patients displaying virological breakthrough or reduced susceptibility to entecavir. In conclusion, UDPS
was not only sensitive and accurate in identifying drug-resistance mutations of HBV but also enabled haplotype analysis of the mutants.
This method may offer signiﬁcant advantages in explaining and predicting the responses of patients with HBV to antiviral therapy.
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Introduction
Nucleoside/nucleotide analogues such as lamivudine, adefovir
and entecavir are widely used for the treatment of chronic
hepatitis B [1–3]. However, the development of drug resis-
tance is a common problem during long-term therapy [4].
Antiviral therapy can cause selection of drug-resistant
mutants of the hepatitis B virus (HBV), leading to treatment
failure and disease progression [4]. Hence, the accurate iden-
tiﬁcation of drug-resistant HBV is vital for the management
of patients with chronic hepatitis B.
Amino acid substitutions conferring drug resistance are
located in the reverse transcriptase region of the HBV poly-
merase gene [1–4]. Resistance to entecavir appears to occur
through a two-hit mechanism, with initial selection of a lami-
vudine-resistance mutation followed by substitutions at addi-
tional residues. Therefore, when identifying HBV mutants
resistant to entecavir, it is important to perform haplotype
analysis to determine whether mutations at multiple residues
are co-located on the same viral genome [5].
At present, the most commonly used methods for detect-
ing HBV drug-resistance mutations are direct sequencing and
reverse hybridization [4]. Direct sequencing can identify all
existing and emerging mutations but only those present in
>20% of the circulating virus population. Reverse hybridiza-
tion can detect mutations with frequencies of 5%, but only a
limited repertoire of well-established mutations. Further-
more, neither of these methods enables haplotype analysis,
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hence precluding the determination of whether multiple
mutations are co-located on the same viral genome.
Recently, several next-generation sequencing technologies
have become available that generate more data than the con-
ventional direct sequencing method [6,7]. The Roche GS
FLX platform achieves this throughput by using emulsion
PCR and simultaneous pyrosequencing on a picolitre scale
[8]. The use of this technology to sequence a given
nucleotide multiple times is referred to as ultra-deep pyrose-
quencing (UDPS) [9,10]. The read length of the GS FLX is
400–500 bp, making it suitable for analysing haplotypes of
entecavir-resistant HBV mutants in which mutations are dis-
persed over a 250-bp range.
In our present study, UDPS was used to detect HBV
drug-resistant mutations in entecavir-treated and treatment-
naive patients. The results were compared with those of
direct sequencing and an exclusive program was developed
to analyse the haplotypes of the HBV mutants.
Patients and Methods
Study subjects
Samples were obtained from 23 entecavir-treated patients
with HBV mutations associated with resistance to lamivu-
dine, adefovir or entecavir that had been detected by direct
sequencing (nos. 1–23). Of these 23 patients, 18 (nos. 1–3,
5, 6, 8, 9, 11–18 and 20–22) had experienced virological
breakthrough (>1 log10 IU/mL increase in serum HBV DNA
from nadir) and two (nos. 7 and 10) exhibited reduced sus-
ceptibility to entecavir (responding at ﬁrst by >1 log10 IU/mL
decrease in serum HBV DNA but stopping to a ﬁxed viral
load later). Samples were also obtained from two entecavir-
treated patients with no HBV drug-resistance mutation
detected by direct sequencing (nos. 24 and 25) and from ﬁve
treatment-naive patients (nos. 26–30).
Of the 25 entecavir-treated patients, 20 were treated with
entecavir after lamivudine failure (no. 2–8, 10–21, and 23),
four were switched from lamivudine to entecavir without
lamivudine failure (nos. 1, 9, 22 and 24) and one (no. 25) had
not been previously treated with lamivudine (Table 1). Viro-
logical breakthrough after entecavir treatment occurred in
15 of the 20 patients with a previous lamivudine failure
(median time to virological breakthrough of 16 months), and
in three of the remaining ﬁve patients (median time to viro-
logical breakthrough of 28 months).
The serum HBV DNA levels at the time of UDPS analysis
were quantiﬁed using a commercially available real-time PCR
assay (Abbott Molecular Inc., Abbott Park, IL, USA) accord-
ing to the manufacturer’s instructions (Table 1).
PCR and UDPS
The HBV DNA was extracted using the QIAamp MinElute
Virus Spin Kit (Qiagen Inc., Valencia, CA, USA) and then
ampliﬁed with eight primer pairs (Table 2). PCR was per-
formed with 1 lL HBV DNA in a 25-lL reaction mixture
containing 1 · PCR buffer (30 mM Tris–HCl; pH 9.0 30 mM
salts consisting of K+ and NH4
+; 2 mM Mg2+; and enhancer
solution), 25 mM dNTPs, 12.5 lM of each primer, and
0.625 U i-Star Taq DNA polymerase (Intron Biotechnology,
Sungnam, Korea). Ampliﬁcation conditions consisted of 95C
for 10 min followed by 35 cycles of denaturation for 30 s at
95C, annealing for 30 s at 55C, and extension for 60 s at
72C, with a ﬁnal 10-min extension at 72C.
The PCR amplicons were puriﬁed with AMPure beads
(Beckman Coulter Inc., Brea, CA, USA) and subjected to
UDPS. Library preparation, emulsion PCR and pyrosequenc-
ing were performed using the GS FLX (454 Life Sciences,
Roche, Bandford, CT, USA), according to the manufacturer’s
instructions. After library preparation, the DNA library was
quantiﬁed using RiboGreen (Invitrogen, Eugene, OR, USA)
and pooled at equimolar concentrations. Following emulsion
PCR, the beads were counted on a Multisizer 3 Coulter
Counter (Beckman Coulter Inc.). Pyrosequencing was per-
formed with a GS FLX 454 Genome Sequencer on the 1/4
region of a 70 · 75 mm Picotiter Plate.
Direct sequencing
The reverse transcriptase region of the HBV polymerase
gene in each sample was analysed by a direct sequencing
method. The PCR was performed with an Absolute HBV DR
(Entecavir) SBT kit (Biosewoom, Seoul, Korea) according to
the manufacturer’s instructions. Direct sequencing was per-
formed on an ABI 3130x1 genetic analyser (Applied Biosys-
tems, Hitachi, Japan).
Analysis of sequence data generated by UDPS
More than 99% of the HBV isolates in Korea are genotype C
[11]. Hence, sequences of each read obtained by UDPS were
aligned to the NC_003977 (http://www.ncbi.nlm.nih.gov/
nuccore/NC_003977) sequence using AMPLICON VARIANT ANA-
LYZER software (Roche). However, because this software is
designed for single-nucleotide polymorphism analysis, we
developed an exclusive program to analyse HBV mutant hapl-
otypes as well as estimate mutation frequencies.
The program ﬁrst loads the sequences of each read
obtained by UDPS, and counts the total number of reads
covering the region in which HBV drug-resistance mutations
are located. Sequences with insertions and deletions are then
considered as follows throughout the correction process:
when insertions or deletions are detected at positions of
CMI Ko et al. Haplotype analysis of drug-resistant HBV mutants by UDPS E405
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E404–E411
other than homopolymer of more than three bases, the
number of reads with a speciﬁc insertion or deletion for
which a quality value (phred-equivalent values for each UDPS
base call) is >20 is counted by each nucleotide position. If
these reads constitute >2% of the total number of reads, the
insertion or deletion is regarded as authentic and the reads
are excluded from calculation of HBV drug-resistance muta-
tion frequency. There were four samples with insertions
(nos. 6, 9, 10 and 29) and they constituted approximately
2.3–3.3% of the reads.
The program then converts the nucleotide sequences to
the amino acid sequences of the HBV polymerase, which is
compared with the NC_003977 sequence to identify muta-
tions. Mutations conferring resistance to antiviral agents
included rtM204I/V, with or without rtL180M, for lamivudine
resistance; rtA181T/V or rtN236T for adefovir resistance;
and a combination of lamivudine-resistance mutations plus
rtI169T, rtV173L, rtT184S/A/I/L/F/G, rtS202G/I or rtM250V
for entecavir resistance. The program counts the number
of reads for each drug-resistant mutant, and the frequency
of each drug-resistance mutation is calculated as the number
of reads with that mutation relative to the total number of
reads covering the rt169–rt250 region.
The cut-off for the mutation frequency was set at 1%.
The reliability of drug-resistance mutations detected at
TABLE 1. Antiviral treatment history before ultra-deep pyrosequencing (UDPS) analysis, serum hepatitis B virus (HBV) DNA
level at the time of UDPS, time to virological breakthrough after entecavir treatment, and historic resistance data by direct
sequencing in the corresponding samples of 30 HBV-infected patients
Patient
no. (sample) Antiviral treatment history (months)
HBV DNA
(IU/mL)
Time to VB
after ETV tx
(months)
Historic resistance
data before UDPS
by direct sequencing
Time of direct
sequencing taken
(months after
ETV tx)
1 LMV (3) ETV (22) 6.3 · 106 18 Not done –
2 LMV (17) LMV + ADV (33) ETV (35) 6.8 · 106 18 L180M, T184L, M204V 18
3 LMV (57) LMV + ADV (42) ETV (22) >1.0 · 109 10 L180M, T184L, M204V 13
4 LMV (21) ADV (31) ETV (15) No tx (5)a 7.2 · 106 – L180M, M204I 15
5 LMV (24) ADV (17) ETV (35) 2.2 · 106 11 L180M, S202G, 204V 21
6 LMV (57) ADV (33) ETV (23) 8.4 · 105 16 L180M, S202G, 204I/V 16
7 LMV (58) ADV (36) ETV (24) 4.7 · 104 – L180M, M204V 13
8 LMV (16) LMV + ADV (31) ETV (24) 2.8 · 107 19 Not done –
9 LMV (24) No tx (36)b ETV (33) 7.4 · 107 34 Not done –
10 LMV (32) ADV (37) ADV + ETV (16) 5.4 · 104 – Not done –
11 LMV (43) ADV (41) ETV (27) 1.1 · 107 15 L180M, M204I 13
12 LMV (26) ADV (28) LMV + ADV (16) ETV (25) 3.0 · 105 16 L180M, S202G, 204V 16
13 LMV (10) ADV (9) ETV (19) 2.0 · 106 16 Not done –
14 LMV (15) ADV (24) ETV (21) 7.2 · 104 21 Not done –
15 LMV (12) ADV (21) LMV + ADV (12) ETV (29) 1.7 · 105 12 V173L, L180M,
T184L, S202G, M204V
15
16 LMV (30) LMV + ADV (10) ETV (21) 1.5 · 107 11 Not done –
17 LMV (18) ADV (47) ETV (21) 3.3 · 105 19 Not done –
18 LMV (42) ETV (16) 3.6 · 106 16 Not done –
19 LMV (28) ETV (7) 6.0 · 105 – Not done –
20 LMV (9) ETV (29) 1.5 · 107 12 Not done –
21 LMV (20) ETV (13) 1.1 · 107 13 Not done –
22 LMV (24) No tx (9)b ETV (28) 2.4 · 107 28 Not done –
23 LMV (9) ETV (4) 5.1 · 104 – M204I 3
24 LMV (36) No tx (27)b ETV (3) No tx (6)b >1.0 · 109 – Not done –
25 ETV (12)c 3.0 · 108 – Not done –
26 >1.0 · 109
27 5.5 · 107
28 >1.0 · 109
29 5.9 · 108
30 2.0 · 108
LMV, lamivudine; ADV, adefovir; ETV, entecavir; tx, treatment; VB, virological breakthrough.
aDue to pregnancy.
bDue to non-compliance.
cIrregular intake.
TABLE 2. Sequences and positions of the primers used for
PCR ampliﬁcation
Primer
name Primer sequence (5¢ ﬁ 3¢) Direction Position
1 - F TCCAACTTGTCCTGGCTAT Forward 352–370
1 - R GCCTTGTAAGTTGGCGAGA Reverse 1097–1115
2 - F CTACCAGCACGGGACCAT Forward 498–515
2 - R GCCTTGTAAGTTGGCGAGA Reverse 1097–1115
3 - F AGAATTGTGGGTCTTTTGG Forward 994–1012
3 - R CAGAGGTGAAGCGAAGTG Reverse 1582–1599
4 - F GGTGGGAAGTAATTTGGAA Forward 2113–2131
4 - R CCAGCCTTCCACAGAGTAT Reverse 2752–2770
5 - F GGCCTATATTTTCCTGCTG Forward 44–62
5 - R ACATAGAGGTTCCTTGAGCA Reverse 535–554
6 - F AACCCTGTTCCGACTACTG Forward 86–104
6 - R GCCTTGTAAGTTGGCGAGA Reverse 1097–1115
7 - F TTGTTTAAAGACTGGGAGGA Forward 1719–1738
7 - R AGTTTCCGGAAGTGTTGAT Reverse 2320–2338
8 - F CTTGGACAAAGGCATTAAAC Forward 2678–2697
8 - R CCTCGAGAAGATTGACGAT Reverse 115–133
Numbering is based on the genotype C strain ayr genome, GenBank accession
number NC_003977.
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frequencies of 1–2% by UDPS was conﬁrmed by counting
the number of reads with a quality value >20 at all three nu-
cleotides of the corresponding mutation.
Results
Drug-resistance mutations of HBV detected by direct
sequencing and UDPS
The average lengths of the reads obtained by UDPS from sam-
ples of 30 HBV-infected patients ranged from 402 to 442 bp,
depending on the segment. The average number of reads cov-
ering the rt169–rt250 region was 1735 (range 451–4526).
The drug-resistance mutations detected by direct
sequencing among the 23 entecavir-treated patients (nos. 1–
23) were associated with the antiviral treatment history of
the patients. Of these 23 patients, 19 (all but nos. 4, 10, 19
and 23) had entecavir-resistance mutations. No drug-resis-
tance mutation was detected by direct sequencing in any of
the ﬁve treatment-naive patients (nos. 26–30).
All drug-resistance mutations detected by direct sequenc-
ing were detected by UDPS. The UDPS also detected addi-
tional drug-resistance mutations not detected by direct
sequencing in 19 of the 30 patients (Table 3). A total of 38
drug-resistance mutations were detected only by UDPS,
including 37 at frequencies <20% and one (V173L from no.
10) at a frequency >20% (23.8%). Of the seven patients in
whom no drug-resistance mutations were detected by direct
sequencing (nos. 24–30), two (nos. 25 and 30) had drug-
resistance mutations detected only by UDPS. The treatment
response of patient no. 25 could not be evaluated because
this patient died 2 months later due to septic shock. Patient
no. 30 continued entecavir treatment and the serum HBV
was undetectable after 15 months without any virological
breakthrough.
Reliability of HBV drug-resistance mutations detected at
frequencies of 1–2% by UDPS
The UDPS detected 14 drug-resistance mutations at frequen-
cies of 1–2% in 11 patients. Of the 508 reads with these 14
mutations, 452 (89%) had quality values >20 at all three nu-
cleotides of the corresponding mutations. Drug-resistance
mutations in these reads were considered to have a high
reliability.
Haplotypes of the drug-resistant HBV mutants
Entecavir-resistance mutations were found to be co-located
on the same viral genome (entecavir-resistant variants) in the
18 patients (nos. 1–3, 5, 6, 8, 9, 11–18, and 20–22) who
had been treated with lamivudine before being started on
TABLE 3. Drug-resistance mutations of hepatitis B virus detected by direct sequencing and additional drug-resistance muta-
tions detected only by ultra-deep pyrosequencing (UDPS), with their frequencies in each patient
Patient no.
(sample)
Drug-resistant mutations detected by
direct sequencing (%a) Drug-resistant mutations detected only by UDPS (%)
1 L180M(99.1), S202G(84.4), M204V(97.2) T184A(1.3), M250V(13.8)
2 L180M(97.3), T184L(97.1), M204V(95.8) A181T(1.7), M204I(1.2)
3 L180M(94.8), T184L(94.8), M204V(94.7) –
4 L180M(29.3), M204I(96.4) –
5 L180M(99.2), T184I(69.9), S202G(97.2), M204V(97.8) T184L(2.0)
6 L180M(97.9), S202G(98.5), M204V(98.0) M204I(1.1)
7 V173L(98.7), L180M(98.9), M204V(99.1) –
8 L180M(98.3), T184L(93.2), M204V(98.1) A181T(1.4), T184F(2.7)
9 V173L(99.4), L180M(99.2), M204V(98.1) M250V(3.9)
10 L180M(42.6), A181V(15.3), M204V(41.6), N236T(21.6) V173L(23.8), M204I(12.3)
11 I169T(68.9), L180M(97.7), T184A(97.3), M204V(97.1) –
12 L180M(98.5), S202G(96.9), M204V(95.1) M204I(1.5)
13 L180M(97.2), S202G(94.3), M204V(93.3) A181T(2.8), T184I(2.6), M204I(1.8)
14 L180M(93.7), T184L(38.5), S202G(51.8), M204V(90.6) A181V(2.5), A181T(1.7), M204I(3.5), N236T(2.1)
15 V173L(36.9), L180M(97.1), T184L(63.5), S202G(23.4), M204V(95.0) A181T(2.4), T184A(4.2), M204I(3.2)
16 L180M(99.3), S202G(98.4), M204V(97.5) T184I(1.7)
17 L180M(98.9), T184A(95.8), M204V(99.2) T184S(3.9)
18 L180M(99.1), S202G(99.6), M204V(99.1) –
19 L180M(39.9), M204I(59.0), M204V(39.3) A181T(1.4)
20 L180M(98.1), T184L(13.4), S202G(77.0), M204V(98.2) I169T(3.6), T184I(1.9)
21 L180M(98.6), S202G(86.7), M204V(97.7) A181T(1.8), T184L(7.1)
22 L180M(99.4), S202G(99.8), M204V(97.5) –
23 M204I(97.7) I169T(1.4), L180M(3.6), A181T(5.0), T184I(1.2), M204V(1.8)
24 – –
25 – A181T(10.4), M204I(3.2)
26 – –
27 – –
28 – –
29 – –
30 – A181T(3.9), M204I(6.1)
a% Analysed by UDPS.
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entecavir and had experienced virological breakthrough
(Table 4). Entecavir-resistant variants constituted >75% of
the circulating virus population in 17 of these 18 patients (all
but patient no. 9). The entecavir-resistant variants observed
were L180M-T184A-M204V, L180M-T184L-M204V,
L180M-T184S-M204V, L180M-T184F-M204V, L180M-T184G-
M204V, L180M-S202G-M204V, L180M-M204V-M250V,
L180M-A184I-M202G-M204V, L180M-M202G-M204V-250V,
I169T-L180M-T184A-M204V, V173L-L180M-T184A-M204V,
V173L-L180M-T184L-M204V, and V173L-L180M-M204V-
M250V.
Partially resistant variant V173L-L180M-M204V was
observed in three patients with a history of previous lamivu-
dine treatment before receiving entecavir. They were patient
no. 9, who had experienced virological breakthrough, and
patients nos. 7 and 10 with reduced susceptibility to enteca-
vir. In patient no. 23, variants of unknown signiﬁcance were
observed. I169T and T184I, which were detected at very
low frequencies by UDPS, were co-located with M204I
(I169T-M204I and T184I-M204I). This patient continued ent-
ecavir treatment and the serum HBV level decreased to 1
log after 6 months. However, the HBV level started to
increase afterwards and reached 7 log after 14 months.
L180M, M204I, M204V, T184I and T184L were detected by
direct sequencing at this point. Mutations conferring resis-
tance to lamivudine or adefovir were detected by UDPS in
four patients (nos. 4, 19, 25 and 30) and no drug-resistance
mutations were detected by UDPS in ﬁve patients (nos. 24,
26–29).
Discussion
Entecavir is widely used for the treatment of chronic hepati-
tis B. As the development of resistance to entecavir requires
multiple mutations in the HBV reverse transcriptase, haplo-
type analysis is essential for the accurate prediction of resis-
tance to this drug. As previously applied, however, haplotype
analysis involves in vitro cloning and sequencing methods that
are too labour-intensive for routine laboratory analysis. On
the other hand, UDPS not only allows the detection of
minor variants but also permits haplotype analysis of drug-
resistant HBV mutants and may therefore be a good alterna-
tive approach.
To date, only three studies have applied UDPS to the
detection of drug-resistance mutations of HBV. Two studies
focused on the detection sensitivity and error rate of UDPS
by using HBV plasmid clones, and both selected 1% as the
cut-off for distinguishing sequencing errors from authentic
minor variants [9,10]. We also demonstrated that UDPS is
highly sensitive in detecting HBV mutations conferring drug-
resistance. Several drug-resistance mutations were detected
at very low frequencies of 1–2%. Approximately 90% of the
reads with these mutations had quality values >20 at all
three nucleotides of the mutations. Hence, a cut-off >1.0%
for the detection of drug-resistance mutations by UDPS
seems appropriate. The other study found that drug-resistant
HBV mutants are commonly present in the liver and serum
of treatment-naive patients in various abundances [12].
However, for the correct interpretation of minor variants,
G-to-A hypermutation induced by host cytidine deaminase
APOBEC3G (apolipoprotein B messenger RNA editing
enzyme, catalytic polypeptide-like 3G) should be considered
[13]. This causes deamination of cytidine bases to uridine in
negative-stranded viral genomes, resulting in G-to-A hyper-
mutation of the virus. G-to-A hypermutated viruses are non-
functional because their replication is inhibited. This type of
mutation was ﬁrst reported in HIV [14] and has recently
been reported for HBV also [15]. The actual incidence of
hypermutated genomes is very low so they are rarely
detected by conventional sequencing analyses. Among the
drug-resistance mutations of HBV, A181T and M204I are
caused by a G-to-A mutation. Hence, the possibility that
some proportion of the A181T and M204I detected only by
UDPS are actually the result of G-to-A hypermutated viruses
cannot be excluded at this stage.
Mutations conferring resistance to entecavir were found
to be co-located on the same HBV genome in all 20 patients
who had experienced virological breakthrough or who exhib-
ited reduced susceptibility to entecavir. In patient no. 10, the
L180M, A181V, M204V and N236T mutations were detected
by direct sequencing, but the presence of these mutations
could not explain this patient’s reduced susceptibility to ente-
cavir. However, UDPS detected an additional V173L muta-
tion at a frequency of 23.8% and haplotype analysis showed
that this mutation was co-located with L180M–M204V,
explaining the patient’s reduced susceptibility to entecavir.
Patient no. 23 responded to entecavir treatment with HBV
DNA level decreasing. Only the M204I mutation was
detected by direct sequencing and additional I169T and
T184I mutations were detected at very low frequencies by
UDPS in this patient. Haplotype analysis showed that each of
these mutations was co-located with M204I. To investigate
whether the virological breakthrough that eventually
occurred in this patient was caused by M204I and the minor-
ity variants or by de novo M204V, haplotype analysis has to
be performed on the HBV strain at the time of virological
breakthrough. Unfortunately, however, no sample at virologi-
cal breakthrough was available for further UDPS. Based
on the results of direct sequencing carried out at the time
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TABLE 4. Haplotypes of drug-resistant hepatitis B virus mutants with frequencies >1% with their estimated load in each
patient
Patient no. (sample) Clinical status Haplotype Frequency (%) Loada (IU/mL)
1 VB 180M-202G-204V 78.2 4.9 · 106
180M-204V-250V 10.3 6.5 · 105
180M-204V 2.4 1.5 · 105
180M-202G-204V-250V 2.3 1.4 · 105
2 VB 180M-184L-204V 92.2 6.3 · 106
3 VB 180M-184L-204V 91.8 9.2 · 108
Wild 2.8 2.8 · 107
4 204I 65.2 4.7 · 106
180M-204I 28.9 2.1 · 106
Wild 1.5 1.1 · 105
5 VB 180M-184I-202G-204V 66.5 1.5 · 106
180M-202G-204V 25.6 5.6 · 105
180M-184L-204V 1.4 3.1 · 104
6 VB 180M-202G-204V 94.7 8.0 · 105
204I 1.1 9.2 · 103
7 Reduced susceptibility 173L-180M-204V 95.1 4.5 · 104
8 VB 180M-184L-204V 90.2 2.5 · 107
180M-184F-204V 2.9 8.1 · 105
180M-204V 1.1 3.1 · 105
9 VB 173L-180M-204V 92.3 6.8 · 107
173L-180M-204V-250V 3.8 2.8 · 106
10 Reduced susceptibility 173L-180M-204V 23.1 1.2 · 104
180M-204V 20.0 1.1 · 104
236T 17.9 9.7 · 103
181V 14.1 7.6 · 103
204I 10.3 5.6 · 103
Wild 2.0 1.1 · 103
180M-204I 1.2 6.5 · 102
11 VB 169T-180M-184A-204V 67.5 7.4 · 106
180M-184A-204V 27.3 3.0 · 106
12 VB 180M-202G-204V 90.7 2.7 · 105
180M-202G-204V-250V 1.1 3.3 · 103
13 VB 180M-202G-204V 88.8 1.8 · 106
180M-184I-202G-204V 1.7 3.4 · 104
14 VB 180M-202G-204V 51.5 3.7 · 104
180M-184L-204V 34.2 2.5 · 104
181V-236T 2.1 1.5 · 103
180M-204V 2.1 1.5 · 103
204I 2.1 1.5 · 103
15 VB 180M-184L-204V 31.7 5.4 · 104
173L-180M-184L-204V 22.4 3.8 · 104
180M-184G-204V 17.6 3.0 · 104
173L-180M-204V 4.2 7.1 · 103
173L-180M-184A-204V 3.4 5.8 · 103
180M-204V 2.8 4.8 · 103
16 VB 180M-202G-204V 95.1 1.4 · 107
180M-184I-202G-204V 1.3 2.0 · 105
180M-204V 1.3 2.0 · 105
17 VB 180M-184A-204V 92.5 3.1 · 105
180M-184S-204V 3.9 1.3 · 104
18 VB 180M-202G-204V 96.7 3.5 · 106
19 204I 69.1 4.1 · 105
180M-204V 25.5 1.5 · 105
20 VB 180M-202G-204V 56.6 8.5 · 106
180M-184L-204V 12.0 1.8 · 106
180M-202G-204V 10.8 1.6 · 106
180M-184I-202G-204V 1.5 2.3 · 105
21 VB 180M-202G-204V 79.7 8.8 · 106
180M-184L-204V 6.5 7.1 · 105
180M-204V 4.3 4.7 · 105
22 VB 180M-202G-204V 94.1 2.3 · 107
180M-184I-202G-204V 1.1 2.6 · 105
23 204I 87.9 4.5 · 104
181T-204I 4.2 2.1 · 103
180M-204I 3.4 1.7 · 103
169T-204I 1.4 7.1 · 102
184I-204I 1.2 6.2 · 102
24 Wild 95.6 9.6 · 108
25 Wild 80.1 2.4 · 108
181T 9.3 2.8 · 107
204I 1.7 5.1 · 106
26 Treatment-naive Wild 97.2 9.7 · 108
27 Treatment-naive Wild 96.8 5.3 · 107
28 Treatment-naive Wild 95.7 9.6 · 108
29 Treatment-naive Wild 95.8 5.7 · 108
30 Treatment-naive Wild 89.9 1.8 · 108
204I 3.1 6.2 · 106
181T 1.2 2.4 · 106
181T-204I 1.0 2.0 · 106
VB, virological breakthrough.
aEstimated mutant loads calculated as per cent of each mutant detected · sample viral load.
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of virological breakthrough, L180M was dominant over
wild-type, M204I and M204V were present in similar propor-
tions, as were T184I and T184L. Considering this ﬁnding, the
previously detected M204I as well as de novo M204V seem to
have played a role in the emergence of virological break-
through in this patient.
Although the rate of resistance to entecavir is known to
be 1.2% after a 5-year treatment in treatment-naive patients
[16], it is much higher in patients previously treated with
lamivudine because the rate of resistance to lamivudine is
quite high [17]. The cumulative incidence of genotypic resis-
tance to entecavir in patients previously treated with lamivu-
dine increases from 6% at year 1 to almost 60% by year 6
[4]. At present in areas endemic for chronic hepatitis B,
entecavir is used more frequently in patients with a previous
history of lamivudine treatment than in patients without any
history of other antiviral treatments. Hence, it is highly prob-
able that lamivudine-resistant HBV mutants are already pres-
ent in patients commencing entecavir.
In treating lamivudine-resistant patients, the European
Association for the Study of the Liver [1] recommends add-
ing tenofovir, or adefovir if tenofovir is not available. The
American Association for the Study of Liver Diseases had
recommended adding adefovir or tenofovir, or stopping lami-
vudine and switching to tenofovir or entecavir [18], although
switching to entecavir has been eliminated in the updated
recommendations [2]. Moreover, a recent multicentre
cohort study has indicated that entecavir should not be used
in patients resistant to lamivudine [19]. On the other hand,
the Asian-Paciﬁc Association for the Study of the Liver still
states that add-on adefovir therapy is indicated and switching
to entecavir is an option for such cases [3]. In some coun-
tries endemic for chronic hepatitis B, this entecavir strategy
is still being implemented for patients with lamivudine resis-
tance. As entecavir-resistant HBV variants emerge easily in
patients with lamivudine resistance, the Asian-Paciﬁc Associa-
tion for the Study of the Liver guidelines should be revised
to discourage the use of entecavir in these patients and pol-
icy should be changed to avoid treatment failures. In Korea,
however, medical insurance does not reimburse for combi-
nation therapy in patients who are resistant to lamivudine,
so these patients are treated with entecavir monotherapy
rather than the combination of lamivudine plus adefovir in
many instances. For this reason, UDPS would be a useful
method of accurately predicting resistance to entecavir in
patients being switched to this drug after developing lamivu-
dine resistance.
Another issue in the management of antiviral resistance is
add-on versus switching therapy. The concept of superiority
of add-on over switching therapy has been adopted for
patients with resistance to lamivudine and adefovir [20].
However, a recent study of patients with chronic hepatitis
B resistant to lamivudine and adefovir has found that ente-
cavir monotherapy results in a more effective suppression
of HBV DNA than lamivudine plus adefovir [21]. This ﬁnd-
ing suggests that most of the HBV mutations conferring
resistance to each drug after sequential monotherapy may
be co-located on the same viral genome. Although a previ-
ous in vitro clonal analysis has indeed found that most of
the HBV drug-resistance mutations are co-located on the
same viral genome, this study analysed only 215 clones from
11 samples [5]. UDPS can yield far more information
because hundreds to thousands of read sequences per sam-
ple can be analysed.
In conclusion, UDPS was highly sensitive and accurate in
identifying drug-resistance mutations of HBV compared with
the conventional direct sequencing method. UDPS detected
mutations at frequencies >1.0% and estimated mutation fre-
quencies by counting an average of 1735 reads. Haplotype
analysis of drug-resistant HBV mutants allowed us to deter-
mine whether the mutations are co-located on the same
viral genome. UDPS identiﬁcation of viral mutants resistant
to drugs may play a signiﬁcant role in explaining and predict-
ing the responses of patients with chronic hepatitis B to an-
tiviral therapy.
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